Drug intelligence / Profile preview

AL6802

Development stage: Unknown
Lead developer: Simcere Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

AL6802 is a small-molecule inhibitor of the epidermal growth factor receptor (EGFR) currently under development by Hangzhou Aidecheng Pharmaceutical Technology (also known as Advenchen Laboratories). It is being investigated for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors. As a targeted therapy, it aims to inhibit the signaling pathways driven by EGFR mutations that promote tumor growth and survival. The drug is currently in Phase 1 clinical development.

Other names: AL6802AL-6802AL 6802

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on AL6802.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL6802.

Explore the full profile